Yuhan recovers license for its non-small cell lung cancer therapy from Luoxin

Published: 2016-12-29 14:09:11

Updated: 2016-12-29 14:09:29

Yuhan Corporation cancelled the technology export agreement of a targeted therapy for non-small cell lung cancer, YH25448, with a Chinese pharmaceutical company Luoxin Biotechnology.

According to Yuhan Coporation, the company made a technology export and co-development agreement of YH25448 for the total USD 120 million, which includes the upfront payment and phased milestones, with Luoxin. Luo...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.